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CD2 triggering of human T lymphocyte activation has been associated with the activation of diKerent interacting protein kinases. including protein 
kinase C (PKC). However the precise roles of 11s phosphorylated substrates arc still unknown. We show here that PKC-dependent and -independent 
pathways arc responsible for the CD2-induced phosphorylatlon of stathmin, a ubiquitous soluble phosphoprotein. most hkely acting as a general 
mtracellular relay integrating various second messenger pathways. The phosphorylated variants of stathmin provide a lingerprint reflecting the 
second messenger pathway(s) stimulated. The respective roles of both PKC and stathmm in the regulation of T lymphocyte proliferation are dis- 
cussed. 
Stathmin: T lymphocyte activation: CD?; Protein kinase C: Protein phosphorylation 
1. INTRODUCTION 
In recent years, studies on T lymphocyte activation 
have defined a number of specific surface molecules 
through which these cells can be stimulated. Beside the 
antigen-specific activation pathway mediated through 
the complex of the T cell receptor (CD3/TCR), pro- 
liferation and effector functions of human T cells can 
also be achieved by stimulating the CD2 antigen, a 
55-kDa glycoprotein [l-3]. We have shown previously 
that CD2 triggering of a soluble-antigen-specific nor- 
mal human CD4’ T lymphocyte clone (P28D) [4] is 
associated \cith the activation of phospholipases C [5] 
and A2 [6], as well as the modulation of adenylate 
cyclase [7]. As in other cellular systems, the second 
messengers elicited are known to stimulate various pro- 
tein kinases among which protein kinase C (PKC) has 
been proposed as a key enzyme in T lymphocyte activa- 
tion (reviewed in [8]), although the precise roles of most 
of its phosphorylated substrates are still unknown. 
We previously identified stathmin [9] as a ubiquitous 
soluble phosphoprotein most likely acting as a general 
intracellular relay integrating various second messenger 
pathways triggered by diverse extracellular signals 
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(re\.ieued in [IO]). Stathmin - also designated pp17 01 
prosolin [1 11, ~18 [12], P19 [13], pp20, pp21 and pp23 
[ 141 and 19 k [ 151 - is present in cells as at least two 
distinct isoforms, yielding several increasingly phos- 
phorylated states (,Ur= 19 000-23 000; pl = 6.2-5.6) 
[16,17] most likely representing a molecular basis for 
signal integration [9,10]. As in \,arious biological 
systems [IO]. expression and phosphorylation of 
stathmin in immune cells ha\e been related to the 
regulation of cell proliferation, either of normal human 
proliferative peripheral lymphocytes [l 1,141 or of T 
leukemic Iymphoblasts (181, as Iveil as to the transfor- 
mation of T leukemic lymphocytes [12]. 
The aim of the present study Mas to further in- 
vestigate the intracellular transduction pathways in- 
volved in the CD2 activation process. The 
phosphorylated variant< of stathmin provide a finger- 
print of the second messenger pathway(s) stimulated. 
We show here that PKC-dependent and -independent 
pathways are responsible for the CD2-induced stathmin 
phosphorylation pattern in the P28D human normal 
CD4’ T cell clone [4]. Thus, ne\\ insights are discussed 
OII the respective roles of both PKC and stathmin in the 
regulation of T lymphocyte proliferation. 
2. MATERIALS AND METHODS 
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CiJG! cells (IO” cells) were stimulated either tvith TPA (100 ng/mif 
(L.C. Serv. Corp., Woburn, USA)or with theX1 l/D66 [19] mitogenic 
pair of anti-CD2 mAb$ as described [S]. After stimulation, the cells 
%ere extensively washed and resuspended in 1.5 ml homogenization 
buffer (Buffer A: 20 mhl Tris-HCI, pH 7.4, 2.5 mM EGTA, 2 mhl 
EDTA, 50 mM 2-mercaptoethanol, 4 &ml leupeptin, 10 pg/ml 
aprotinin), and sonicated on ice for 30 s. Aliquots (I ml) of cytosolic 
and particulate fractions, separated by centrifugation as described 
1201, were applied to I ml DE-52 cellulose columns equilibrated with 
Bul’i’er A. After washing, the columns were elured with 2 ml of Buffer 
A containing 0.12 M NaCl. The protein content of the eluate xas 
determined by spot fIaoromeiry [Zl). 
2.2 L PKC assffj 
PKC activiry in cytosol and particulate fractions was assayed by 
measuring Ca” /phospholipid-dependent incorporation of “P from 
[T-“PJATP (110 TBq/mmol) (Amersharn) into histone Type 111-S 
(Sigma) according to [20] with fe\v modifications. The assay system 
contained 40 mM HEPES, pH 7.4, S mM Mg’ -acetate, 5 pg cy~osol- 
or particulate-protein, and 20 pg histonc in 100 ~1, with the addition 
of X jig/ml PS, 0.8 &ml DA<;, and CaCI; to a final concentration 
of 2.50 &l. Reactions were initiated by the addition of 1 nmoi 
[yi2PjATP (0.5-l x 10h cpm), run for 3 min at 30°C and terminated 
by blotting the protein onto Whatman P81 paper. The PKC activity 
in the particulate fraccrion was measured as the stimulated activity 
(pmot “P transferredimirlimS protein in the presence of the three 
aliosferic effecters Ca’* , PS, D.AC) minus basal acrkity iin the 
presence of Ca’- + PS only). 
‘2PO~3 _ -labeling was performed by preincubating cells for 4 h with 
5.55 MBq “POj’- (CEA, France)/S x IOh cells in 250 11 of 
phosphate-free medium, TPA or CD2 mAb$ being added for the last 
10 min. The labeling was stopped, and samplei were analyzed by two- 
dimensional polyacrylamide gel elrctrophorcsis (ZD-PAGE) as 
Incubation time (min) 
Fig. 1. CD&?-stimulated translocation of PKC activity to the par- 
ticulate fraction in P28D T cells. Intact P2XLI T cells were incubated 
for the indicated times at 37°C in the presence of either TPA (100 
ng/rnl) (open bars) or anti-CD2 mAbs (Xl I + D66: SO pgiml each) 
(hatched bars). The PKC activity in the particulate fraction was 
measured as described in section 2. Values are the mean triplicate 
from one experiment out of three giving similar results, and corres- 
pond to the specific PKC activity in the presence of Ca’ ‘, PS and 
DnG, minus the activity in the absence of DAG. 
described 122,233. The isoelectric focusing gels contained 2% am- 
pholirres (LKB), pH 5-7 and 3-10 (4:1). The second dimension was 
run on 13% acrylamide gels. The same amount af trichloroacetic 
acid”.precipitable radioactivity was used for each sample within a 
given experiment, allowing direct comparisan of auroradiogram,. 
J. RESULTS 
To evaluate the involvement of PKC in the 
CD&triggered activation of the P28D human normal 
CD4’ T cell clone, we first examined the membrane 
translocation of the enzyme. As presented in Fig. 1, 
TPA (IO0 ng/ml), a known activator of PKC, caused a 
rapid increase of PKC activity in the particulate frac- 
tion within 1 min, this effect being sustained even after 
60 min of treatment with TPA (not shown). Similarly, 
activation of P28D T cells by the mitogenic pair of anti- 
CD2 mAbs also induced a rapid rise of PKC activity in 
the particulate fraction. The jnvolv~ment of PKC ac- 
tivation foI~o~~ng the CDZtriggering of T lymphocytes 
is thus clearly confirmed in the P28D T celi clone. 
TO further evaluate the relative contribution of PKC 
in the activation of T cells through the CD2 pathway, 
we analysed the phosphorylation pattern of stathmin, 
previously proposed to reflect the activation of diverse 
transduction pathways as well as their interactions 
[9,10,22,23]. 
Incubation of P28D T cells with 3”PO;r3- resuited in 
rhe ““P-labeling of the Pt and, to a lesser extent, P2 
spots of stathmin (IW~= I9 OOO), detected by 2D-PAGE 
autoradiography (Figs. 2 and 3) and corresponding to 
increasingly phosphorylated states of its alpha and beta 
isoforms [ 161. 
‘Treatment of ‘2P043--prelabeled P28D T cells with 
TPA (100 ng/ml, 10 min) stimulated the incorporation 
of “P mostly into Pl and P2, but also into the most 
basic spots of two additional sets (‘16’ and ‘17’) of 
stathmin phosphorylated forms [ 171 (Fig, 3). Indeed a 
slight “P-labeling of spot 16 (M, = 2 1 000 (Fig. 3) was 
induced, as wet1 as a very weak effect on spot 17 
(IW~ = 23 O&I), detectable on the original autoradio- 
grams. Beside these effects, TPA atso strongly 
stimulated the phosp~~ory~ation of an 8O-kDa 
phosphoprotein (Fig. 2) corresponding most likely to 
the protein also designated MARCKS, a major 
substrate for PKC in various cell systems [24]. 
When 32PO~3 - -prelabeled P28D T cells were treated 
with CD2 mAbs for 10 min, the phosphorylation of 
several proteins detected on 2D-PAGE autoradiograms 
was stimulated, including the 80-kDa FKC-substrate 
(Fig. 2). CD2 triggering resulted also in an increased 
phosphoryiation of stathmin into its forms yielding 
spots PI, Pt, 16 and also 17 (Fig. 3). Incorporation into 
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Fig. 2. TPA- and CDZ-induced parterns of phosphorylation in intac[ P280 T lymphocytes. PXD T lymphocyles \~;ere labeled v.iih “t’01 TOI- 
4 h and rhen treated or not (C), with TPA (100 ng/ml) or anti-CD22 mAb5 (Xl I + D-56. 50 l~g,‘rnl each) for 10 min. The box on the ?D-PAGE 
auroradiogram (left) indicates the area ofstathmin spots shown in detail in Fig. 3. The open ha]- undertincc the wren of the maior 80 hDa-X1.4KC‘KS- 
sub5lrate of PKC. 
Pl and P2 was smaller than the effect obtained with 
TPA. On the other hand, phosphorylation of spot 16 
was much more stimulated than in TPA-treated cells, 
and a more acidic, presumably more phospiiorylated 
form of set ‘16’ could also be detected on the 
autoradiograms. In addition, CD2 triggering induced a 
ciear incorporation of “P also into spot 17. 
4. DISCUSSION 
We and others have recently associated the 
CD2-triggered T lymphocyte alternative pathway of ac- 
tivation with various signal transduction pathways 
[5-7,2_5,26]. However, the relative contribution of each 
pathway to the activation process is still a matter for in- 
vestigation. Therefore, in the present work, CD2 ac- 
tivation was rciatcd to the regulation of stathmin 
phosphorylation, a protein present in the cells as at least 
two distinct isoforms [16] yielding several sets of 
phosphorylated forms whose pattern reflects the activa- 
tion of diverse signal transduction pathways [ 10,22,23]. 
We first clearly demonstrated the involvement of 
PKC in the CD2triggered activation of the normal 
human CD4 + T lymphocyte P28D clone, as proved by 
the increase of PKC activity in the particulate fraction, 
and of the phosphorylation of the 80 kDa PKC- 
substrate MARCKS [24]. in our hands, high CaZ+ con- 
centrations were found more effective to assay the PKC 
translo~ation. This result is slightly different from that 
reported in Jurkat cells [27]. However this could reflect 
the difference in the Ca’+-dependence of PKC 
isoforms present in different cell types since the o(- 
isoform is predominant in the transformed Jurkat cell 
line whereas the fl-isoform of PKC is more expressed in 
normal T lymphoblasts [28] and thus most likely in 
P28D T cells. 
CD2 stimulation of T lymphocytes has been shown to 
induce a rapid PKC-dependent phosphorylation of the 
82 
-,-subunit and to a lesser extent of the &subunit of the 
CD3 antigen, as well as phosphorylation of CD4, CD8, 
CD45 and of class I molecules of the major histocom- 
patibility complex (reviewed in [29]). Intracytosolic 
molecules are also rapidly phosphorylated during a 
CDZ-activated response, including the X0 kDa- 
MARCKS protein. Finally CD2 triggering was related 
also to tyrosine phosphorylation [30-321. Inrerestingly, 
C 
TPA 
CD2 
17, 
If% 
PI P2 
Fig. 3. TPA- and C‘D?-induced parlernr ot’,stathmin phosphorylation. 
intact P28D r lymphocyrc5 were labeled Bith “PO,‘- i’or 3 h and 
then treated or not (C), Mith TPA (100 ng/ml) or anti-CD2 mAhs 
(Xl 1 + D66, 50 pg/ml each) i‘or 10 min. The areas ot ZD-PAGE 
autoradiogram, 35 boscd in Fig. 2 are prexnred. 1’1, P? and P3 are 
the three increasingI> phosphorylated 19 kDa forms of srathmin, 
Lvhcreas arrowheads numbered 16 and 17 point IO the corresponding 
sraihmin-derived pho\phoprorcin ~$5, at 21 aild 23 kDa, rcspeciively. 
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CD2 stimulation of T lymphocytes also induces the 
phosphorylation of stathmin, a ubiquitous cytosolic 
protein whose expression and/or phosphorylation have 
been related to the regulation of either proliferation, 
differentiation or of differentiated functions of various 
cell types [lo]. The phosphorylated variants of stathmin 
most likely represent the molecular support for signal 
integration [lo]. In this respect, we found that stathmin 
is also expressed in the P28D normal human CD4’ T 
lymphocyte clone, in agreement with recent reports on 
resting peripheral T lymphocytes [ 111. 
Comparison of stathmin phosphorylation patterns 
obtained after stimulation of cells with either TPA, a 
potent activator of PKC, or after CD2 triggering allow- 
ed to gain insight in the involvement of both PKC and 
stathmin in CD2-triggered T cell activation. Indeed 
both TPA and CD2 triggering of P28D T cells led to 
characteristic, partially overlapping but quantitatively 
and qualitatively distinct phosphorylation patterns of 
stathmin isoforms. As compared to the action of TPA, 
CD2 triggering induced a somewhat less intense 
stimulation of 32P-incorporation into the 19 kDa forms 
of stathmin Pl and P2, and conversely a much stronger 
incorporation into the higher molecular weight sets ‘16’ 
and ‘17’. In Jurkat cells phosphorylation of stathmin 
forms ‘ 16’ and ‘ 17’ has been related to the activation of 
aCa’+ -dependent kinase [33], which might then also be 
involved in CD2 action. Thus the characteristic 
phosphorylation pattern of stathmin may indeed reflect 
the different transduction pathways involved in a con- 
sidered activation signal. In this respect, our results 
clearly indicate that the activation via CD2 involves 
other kinase(s) beside PKC. 
In CD2-stimulated P28D T cells, stathmin 
phosphorylation is related here to a signal positively 
associated with T cell activation. This is also the case in 
Jurkat cells [33] and in UW-4B, an IL2-dependent cell 
line where it is related to stimulation by IL-2 [34]. Con- 
versely, in proliferating IL-2 dependent PBL as well as 
in several tumoral T cell lines, phosphorylation of 
stathmin in response to TPA alone or together with the 
Ca2+ lonophore A23187 has also been associated with 
down-regulation of DNA synthesis [11,18]. Thus, as in 
many non-immunological biological systems, 
phosphorylation of stathmin is taking place in response 
to activation of diverse intracellular pathways. Con- 
sidered together, our data strongly support the propos- 
ed role of relay for stathmin, the final effect depending 
on the state of proliferation and/or differentiation of 
the cells considered [lo]. 
The present analysis of stathmin phosphorylation in 
a normal human T cell clone gives further clues on the 
PKC-dependent and independent intracellular 
mechanisms involved in CD2-regulation of T lym- 
phocyte proliferation. Further pharmacological 
analysis of the different kinases responsible for the 
various phosphorylation patterns of stathmin, and cor- 
responding to physiological perturbations of T lym- 
phocytes will give new insights on signal transduction 
pathways involved in T lymphocyte acti0ation. In this 
respect the potential of stathmin as a new tool should be 
emphasized. Finally it also further documents the pro- 
posed ubiquitous role of stathmin as an intracellular 
relay for extracellular agents, integrating diverse second 
messenger pathways. 
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